Filter By
Filter By
Category: Reagents
Filter By
Reference: R1005-.1
€0.00
(tax incl.)
Better performance of firefly luciferase mRNA modified by ARCA, 5mCTP and ΨUTP, inhibiting RNA-mediated innate immune activation, stable and efficient expression efficiency, used as an experimental control.
Reference: R1005-1
€0.00
(tax incl.)
Better performance of firefly luciferase mRNA modified by ARCA, 5mCTP and ΨUTP, inhibiting RNA-mediated innate immune activation, stable and efficient expression efficiency, used as an experimental control.
Reference: R1005-5
€0.00
(tax incl.)
Better performance of firefly luciferase mRNA modified by ARCA, 5mCTP and ΨUTP, inhibiting RNA-mediated innate immune activation, stable and efficient expression efficiency, used as an experimental control.
Reference: R1006-.1
€0.00
(tax incl.)
Used with guideRNA for site-specific DNA cleavage in genome editing
Reference: R1006-1
€0.00
(tax incl.)
Used with guideRNA for site-specific DNA cleavage in genome editing
Reference: R1006-5
€0.00
(tax incl.)
Used with guideRNA for site-specific DNA cleavage in genome editing
Reference: R1007-.1
€0.00
(tax incl.)
New modification with better performance --- direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control to study transfection and expression in mammalian cells.
Reference: R1007-1
€0.00
(tax incl.)
New modification with better performance --- direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control to study transfection and expression in mammalian cells.
Reference: R1007-5
€0.00
(tax incl.)
New modification with better performance --- direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control to study transfection and expression in mammalian cells.
Reference: R1008-.1
€0.00
(tax incl.)
5-moUTP-modified mRNA with better performance, Cy3 tag, direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control and tool for determining mRNA delivery and localization.
Reference: R1008-1
€0.00
(tax incl.)
5-moUTP-modified mRNA with better performance, Cy3 tag, direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control and tool for determining mRNA delivery and localization.
Reference: R1008-5
€0.00
(tax incl.)
5-moUTP-modified mRNA with better performance, Cy3 tag, direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control and tool for determining mRNA delivery and localization.
Reference: R1009-.1
€0.00
(tax incl.)
5-moUTP-modified mRNA with better performance, Cy5 tag, direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control and tool for determining mRNA delivery and localization.
Reference: R1009-1
€0.00
(tax incl.)
5-moUTP-modified mRNA with better performance, Cy5 tag, direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control and tool for determining mRNA delivery and localization.
Reference: R1009-5
€0.00
(tax incl.)
5-moUTP-modified mRNA with better performance, Cy5 tag, direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control and tool for determining mRNA delivery and localization.
Reference: R1010-.1
€0.00
(tax incl.)
Firefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP and Cy5-utp, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation
Reference: R1010-1
€0.00
(tax incl.)
Firefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP and Cy5-utp, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation
Reference: R1010-5
€0.00
(tax incl.)
Firefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP and Cy5-utp, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation
Reference: R1011-.1
€0.00
(tax incl.)
EGFP mRNA with Cap 1 structure, modified by 5-moUTP and Cy5-utp, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation
Reference: AG-CN2-0001-M001
€0.00
(tax incl.)
Non-peptidic anti-diabetic agent. Receptor-selective glucagon antagonist. Free radical species (·OH, R·) and singlet oxygen (1O2) scavenger. Mycotoxin. Cytotoxic. Antioxidant. Inhibitor of botulinum neurotoxin...
Reference: R1011-1
€0.00
(tax incl.)
EGFP mRNA with Cap 1 structure, modified by 5-moUTP and Cy5-utp, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation
Reference: AG-CN2-0011-M001
€0.00
(tax incl.)
Prenylated 4-hydroxycoumarin. Anti-tumor compound. Cytotoxic. Stimulator of tubulin polymerization in vitro. Inhibitor of colchicine binding to tubulin. Antitubercular antibiotic with potent antibacterial activity....
Reference: R1011-5
€0.00
(tax incl.)
EGFP mRNA with Cap 1 structure, modified by 5-moUTP and Cy5-utp, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation
Reference: AG-CN2-0011-M005
€0.00
(tax incl.)
Prenylated 4-hydroxycoumarin. Anti-tumor compound. Cytotoxic. Stimulator of tubulin polymerization in vitro. Inhibitor of colchicine binding to tubulin. Antitubercular antibiotic with potent antibacterial activity....
Reference: R1012-.1
€0.00
(tax incl.)
Better performance of firefly luciferase mRNA modified by ARCA and 5-moUTP, inhibiting RNA-mediated innate immune activation, stable and efficient expression efficiency, used as an experimental control.
Reference: AG-CN2-0011-M010
€0.00
(tax incl.)
Prenylated 4-hydroxycoumarin. Anti-tumor compound. Cytotoxic. Stimulator of tubulin polymerization in vitro. Inhibitor of colchicine binding to tubulin. Antitubercular antibiotic with potent antibacterial activity....
Reference: R1012-1
€0.00
(tax incl.)
Better performance of firefly luciferase mRNA modified by ARCA and 5-moUTP, inhibiting RNA-mediated innate immune activation, stable and efficient expression efficiency, used as an experimental control.
Reference: AG-CN2-0018-M005
€0.00
(tax incl.)
Protein transport from ER to Golgi inhibitor. ADP-ribosylation factor (Arf) inhibitor. Cytotoxic. Antibiotic. Antiviral. Apoptosis inducer. Antitumor compound. Intracellular collagen degradation inhibitor. Reviews.
Reference: R1012-5
€0.00
(tax incl.)
Better performance of firefly luciferase mRNA modified by ARCA and 5-moUTP, inhibiting RNA-mediated innate immune activation, stable and efficient expression efficiency, used as an experimental control.
Reference: AG-CN2-0018-M010
€0.00
(tax incl.)
Protein transport from ER to Golgi inhibitor. ADP-ribosylation factor (Arf) inhibitor. Cytotoxic. Antibiotic. Antiviral. Apoptosis inducer. Antitumor compound. Intracellular collagen degradation inhibitor. Reviews.
Reference: R1013-.1
€0.00
(tax incl.)
Firefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.
Reference: AG-CN2-0018-M025
€0.00
(tax incl.)
Protein transport from ER to Golgi inhibitor. ADP-ribosylation factor (Arf) inhibitor. Cytotoxic. Antibiotic. Antiviral. Apoptosis inducer. Antitumor compound. Intracellular collagen degradation inhibitor. Reviews.
Reference: R1013-1
€0.00
(tax incl.)
Firefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.
Reference: AG-CN2-0019-C100
€0.00
(tax incl.)
Antibiotic. PKC, PKA and PKG inhibitor. Shows neurotropic activity by inducing neurite outgrowth. Highly potent cell permeable CaM kinase and phosphorylase inhibitor. Tyrosine protein kinase inhibitor of the TRK...
Reference: R1013-5
€0.00
(tax incl.)
Firefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.
Reference: AG-CN2-0019-M001
€0.00
(tax incl.)
Antibiotic. PKC, PKA and PKG inhibitor. Shows neurotropic activity by inducing neurite outgrowth. Highly potent cell permeable CaM kinase and phosphorylase inhibitor. Tyrosine protein kinase inhibitor of the TRK...
Reference: R1015-.1
€0.00
(tax incl.)
Used with guideRNA for site-specific DNA cleavage in genome editing.
Reference: AG-CN2-0020-M005
€0.00
(tax incl.)
Antibiotic. High affinity ionophore for monovalent cations such as H+, K+, Na+, Pb2+. Shows antibacterial (Gram-positive), antifungal, antitumor and antiviral activity. Disrupts membrane potential of mitochondria....
Reference: R1015-1
€0.00
(tax incl.)
Used with guideRNA for site-specific DNA cleavage in genome editing.
Reference: AG-CN2-0020-M025
€0.00
(tax incl.)
Antibiotic. High affinity ionophore for monovalent cations such as H+, K+, Na+, Pb2+. Shows antibacterial (Gram-positive), antifungal, antitumor and antiviral activity. Disrupts membrane potential of mitochondria....
Reference: R1015-5
€0.00
(tax incl.)
Used with guideRNA for site-specific DNA cleavage in genome editing.
Reference: AG-CN2-0021-M001
€0.00
(tax incl.)
Antibiotic. Protein tyrosine kinase inhibitor. Has antifungal, antimalarial, antiangiogenic (in vivo), anti-inflammatory and antiviral activity. Cyclooxygenase-2 (COX-2) expression inhibitor without affecting COX-1...
Reference: R1016-.1
€0.00
(tax incl.)
EGFP mRNA with Cap 1 structure, modified by 5-moUTP,providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.
Reference: A1266-5
€0.00
(tax incl.)
MTOR inhibitor,potent,ATP-competitive and cell-permeable
Reference: AG-CN2-0021-M005
€0.00
(tax incl.)
Antibiotic. Protein tyrosine kinase inhibitor. Has antifungal, antimalarial, antiangiogenic (in vivo), anti-inflammatory and antiviral activity. Cyclooxygenase-2 (COX-2) expression inhibitor without affecting COX-1...
Reference: R1016-1
€0.00
(tax incl.)
EGFP mRNA with Cap 1 structure, modified by 5-moUTP,providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.
Reference: A1266-10
€0.00
(tax incl.)
MTOR inhibitor,potent,ATP-competitive and cell-permeable
Reference: AG-CN2-0022-C100
€0.00
(tax incl.)
Antibiotic. Antifungal and anti-yeast activity. Inhibits platelet aggregation induced by collagen or ADP. Has no effect on thrombin-induced platelet aggregation. Potent, cell permeable, reversible, ATP-competitive and...
Reference: R1016-5
€0.00
(tax incl.)
EGFP mRNA with Cap 1 structure, modified by 5-moUTP,providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.
Reference: A1266-25
€0.00
(tax incl.)
MTOR inhibitor,potent,ATP-competitive and cell-permeable
Reference: AG-CN2-0022-C500
€0.00
(tax incl.)
Antibiotic. Antifungal and anti-yeast activity. Inhibits platelet aggregation induced by collagen or ADP. Has no effect on thrombin-induced platelet aggregation. Potent, cell permeable, reversible, ATP-competitive and...
Reference: R1017-.1
€0.00
(tax incl.)
mCherry mRNA with Cap 1 structure, modified by 5mCTP/ψUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.
Reference: A1266-50
€0.00
(tax incl.)
MTOR inhibitor,potent,ATP-competitive and cell-permeable
Reference: AG-CN2-0022-M001
€0.00
(tax incl.)
Antibiotic. Antifungal and anti-yeast activity. Inhibits platelet aggregation induced by collagen or ADP. Has no effect on thrombin-induced platelet aggregation. Potent, cell permeable, reversible, ATP-competitive and...
Reference: R1017-1
€0.00
(tax incl.)
mCherry mRNA with Cap 1 structure, modified by 5mCTP/ψUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.
Reference: AG-CN2-0022-M005
€0.00
(tax incl.)
Antibiotic. Antifungal and anti-yeast activity. Inhibits platelet aggregation induced by collagen or ADP. Has no effect on thrombin-induced platelet aggregation. Potent, cell permeable, reversible, ATP-competitive and...
Reference: R1017-5
€0.00
(tax incl.)
mCherry mRNA with Cap 1 structure, modified by 5mCTP/ψUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.
Reference: AG-CN2-0023-M001
€0.00
(tax incl.)
Antibiotic. Potent anti-neutrophil agent with cardioprotective effects. mTOR, DNA-PK, phosphatidylinositol 4-kinases, myosin light chain kinase (MLCK) and mitogen-activated protein kinase (MAPK) inhibitor at high...
Reference: R1018-.1
€0.00
(tax incl.)
Firefly Luciferase mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.
Reference: AG-CN2-0023-M005
€0.00
(tax incl.)
Antibiotic. Potent anti-neutrophil agent with cardioprotective effects. mTOR, DNA-PK, phosphatidylinositol 4-kinases, myosin light chain kinase (MLCK) and mitogen-activated protein kinase (MAPK) inhibitor at high...